Literature DB >> 23613110

Impaired GABAergic inhibition in the prefrontal cortex of early postnatal phencyclidine (PCP)-treated rats.

Celia Kjaerby1, Brian V Broberg2, Uffe Kristiansen3, Nils Ole Dalby4.   

Abstract

A compromised γ-aminobutyric acid (GABA)ergic system is hypothesized to be part of the underlying pathophysiology of schizophrenia. N-methyl-D-aspartate (NMDA) receptor hypofunction during neurodevelopment is proposed to disrupt maturation of interneurons causing an impaired GABAergic transmission in adulthood. The present study examines prefrontal GABAergic transmission in adult rats administered with the NMDA receptor channel blocker, phencyclidine (PCP), for 3 days during the second postnatal week. Whole-cell patch-clamp recordings from pyramidal cells in PCP-treated rats showed a 22% reduction in the frequency of miniature inhibitory postsynaptic currents in layer II/III, but not in layer V pyramidal neurons of the prefrontal cortex. Furthermore, early postnatal PCP treatment caused insensitivity toward effects of the GABA transporter 1 (GAT-1) inhibitor, 1,2,5,6-tetrahydro-1-[2-[[(diphenyl-methylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid, and also diminished currents passed by δ-subunit-containing GABAA receptors in layer II/III pyramidal neurons. The observed impairments in GABAergic function are compatible with the alteration of GABAergic markers as well as cognitive dysfunction observed in early postnatal PCP-treated rats and support the hypothesis that PCP administration during neurodevelopment affects the functionality of interneurons in later life.
© The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  NMDA receptor antagonist; development; electrophysiology; frontal cortex; interneuron

Mesh:

Substances:

Year:  2013        PMID: 23613110     DOI: 10.1093/cercor/bht109

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  10 in total

1.  Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.

Authors:  Toshihiro Nomura; Yoshihiro Oyamada; Herman B Fernandes; Christine L Remmers; Jian Xu; Herbert Y Meltzer; Anis Contractor
Journal:  Neuropharmacology       Date:  2015-04-30       Impact factor: 5.250

2.  Phencyclidine administration during neurodevelopment alters network activity in prefrontal cortex and hippocampus in adult rats.

Authors:  Celia Kjaerby; Nanna Hovelsø; Nils Ole Dalby; Florence Sotty
Journal:  J Neurophysiol       Date:  2017-05-24       Impact factor: 2.714

3.  Modified climbing fiber/Purkinje cell synaptic connectivity in the cerebellum of the neonatal phencyclidine model of schizophrenia.

Authors:  Maxime Veleanu; Beetsi Urrieta-Chávez; Séverine M Sigoillot; Maëla A Paul; Alessia Usardi; Keerthana Iyer; Marine Delagrange; Joseph P Doyle; Nathaniel Heintz; Carine Bécamel; Fekrije Selimi
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-19       Impact factor: 12.779

4.  Antioxidant Treatment in Male Mice Prevents Mitochondrial and Synaptic Changes in an NMDA Receptor Dysfunction Model of Schizophrenia.

Authors:  Aarron Phensy; Christopher Driskill; Karen Lindquist; Lan Guo; Vivek Jeevakumar; Bryan Fowler; Heng Du; Sven Kroener
Journal:  eNeuro       Date:  2017-08-17

5.  Anticonvulsive evaluation of THIP in the murine pentylenetetrazole kindling model: lack of anticonvulsive effect of THIP despite functional δ-subunit-containing GABAA receptors in dentate gyrus granule cells.

Authors:  Charlotte Simonsen; Kim Boddum; Nadia L von Schoubye; Alissa Kloppenburg; Kasper Sønderskov; Suzanne L Hansen; Uffe Kristiansen
Journal:  Pharmacol Res Perspect       Date:  2017-08

6.  TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia.

Authors:  Lakshmi Rajagopal; Mei Huang; Eric Michael; Sunoh Kwon; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2018-07-23       Impact factor: 7.853

7.  A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment.

Authors:  Simon R O Nilsson; Pau Celada; Kim Fejgin; Jonas Thelin; Jacob Nielsen; Noemí Santana; Christopher J Heath; Peter H Larsen; Vibeke Nielsen; Brianne A Kent; Lisa M Saksida; Tine B Stensbøl; Trevor W Robbins; Jesper F Bastlund; Timothy J Bussey; Francesc Artigas; Michael Didriksen
Journal:  Psychopharmacology (Berl)       Date:  2016-03-17       Impact factor: 4.530

8.  The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.

Authors:  Linda J Bristow; Amy E Easton; Yu-Wen Li; Digavalli V Sivarao; Regina Lidge; Kelli M Jones; Debra Post-Munson; Christopher Daly; Nicholas J Lodge; Lizbeth Gallagher; Thaddeus Molski; Richard Pieschl; Ping Chen; Adam Hendricson; Ryan Westphal; James Cook; Christiana Iwuagwu; Daniel Morgan; Yulia Benitex; Dalton King; John E Macor; Robert Zaczek; Richard Olson
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

9.  Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia.

Authors:  Philip Lr Gaskin; Maria Toledo-Rodriguez; Stephen Ph Alexander; Kevin Cf Fone
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-03       Impact factor: 5.176

10.  Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia.

Authors:  Kazu Nakazawa; Vivek Jeevakumar; Kazuhito Nakao
Journal:  NPJ Schizophr       Date:  2017-02-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.